Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects
ChemMedChem · 2026-01 · 21 (2)
DOI: 10.1002/cmdc.202500960 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 04.02.2026. Verfasst von Daniela Passeri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Tes Pharma, S.r.l., Via Giovine Italia 1, 06073, Solomeo (PG), Italy. Hauptthemen laut MEDLINE: Receptors, Cytoplasmic and Nuclear, Chenodeoxycholic Acid, Drug Discovery. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The Farnesoid X receptor (FXR) is a bile acid‐activated nuclear receptor that represents an important therapeutic target for gut‐liver diseases and metabolic disorders. Recently, FXR partial agonists have gained attention for their potential to minimize side effects resulting from receptor over‐activation. In this study, we report the design, synthesis, and biological evaluation of novel obeticholic acid (OCA) derivatives as selective FXR modulators. Structural modifications at the C3 α position and the side chain of the bile acid scaffold led to the identification of valine derivatives 2 and 16 as metabolically stable and safe FXR modulators with reduced agonist efficacy. Further molecular dynamics simulations revealed that these compounds induce distinct conformational changes within the FXR ligand‐binding domain, consistent with their partial agonist behavior and resulting in moderate modulation of FXR target genes. Unlike OCA, both compounds failed to activate other steroid‐responsive receptors, including MRGPRX4 (hX4), a G‐protein‐coupled receptor implicated in itching in cholestatic patients, supporting their potential as safer FXR modulators with a reduced risk of pruritus‐related side effects. Overall, this study elucidates key structure–activity relationships governing FXR partial agonism and hX4 binding and offers valuable chemical tools for the development of FXR‐targeted therapeutics with improved safety profiles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tes Pharma, S.r.l., Via Giovine Italia 1, 06073, Solomeo (PG), Italy.
- Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06123, Perugia, Italy.
- Intercept Pharmaceuticals, Inc., 3636 Nobel Drive, San Diego, California, CA 92122, USA.
ORCID-Profile: Antimo Gioiello
Zitieren
APA
Passeri, D., Cerra, B., Carotti, A., Greco, F., Piermarini, S., Colliva, C., Liscio, P., De Franco, F., Adorini, L., Erickson, M. R., Pellicciari, R., & Gioiello, A. (2026). Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects. ChemMedChem, 21(2). https://doi.org/10.1002/cmdc.202500960
Vancouver
Passeri D, Cerra B, Carotti A, Greco F, Piermarini S, Colliva C, et al. Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects. ChemMedChem. 2026;21(2). doi:10.1002/cmdc.202500960
BibTeX
@article{Passeri2026,
author = {Passeri, Daniela and Cerra, Bruno and Carotti, Andrea and Greco, Francesco and Piermarini, Sara and Colliva, Carolina and Liscio, Paride and De Franco, Francesca and Adorini, Luciano and Erickson, Mary Ruth and Pellicciari, Roberto and Gioiello, Antimo},
title = {Structure‐Based Discovery of Obeticholic Acid Derivatives as Novel Farnesoid X Receptor Partial Agonists with Improved Selectivity and Reduced Off‐Target Effects},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {2},
doi = {10.1002/cmdc.202500960}
}
EUVIMED